Haosun Received FDA First Adequate Letter for Desvenlafaxine Succinate DMF

We are pleased to announce that in February, our Desvenlafaxine Succinate USDMF received the DMF First Adequate Letter from the USFDA.

This significant milestone confirms that our DMF has successfully passed a full scientific review by the Agency and is now deemed adequate to support an ANDA approval.

We remain committed to providing high-quality pharmaceutical ingredients to support our partners in bringing essential medicines to market. 🌟